<DOC>
	<DOCNO>NCT00470171</DOCNO>
	<brief_summary>This phase II study direct individual benefit . It randomize , double blind placebo control study whose aim evaluate efficacy tolerance ursodesoxycholic acid patient diagnose non-alcoholic steatohepatitis . The hepatoprotective effect ursodesoxycholic acid may ameliorate hepatic impairment associate non-alcoholic steatohepatitis lead subsequent significant decrease transaminase elevation non-invasive marker hepatic fibrosis A positive response define significantly large decrease average ALAT level time inclusion study end treatment ursodesoxycholic acid group compare placebo group . The duration study 12 month . An end treatment evaluation ( EoT ) take place end 12th month treatment .</brief_summary>
	<brief_title>Pilot Study Ursodesoxycholic Acid Non-Alcoholic Steatohepatitis</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Greater 18 year age . Hepatic biopsy consistent nonalcoholic steatohepatitis : presence &gt; 20 % steatosis associate hepatocyte swell and/or intralobular necrosis within last 18 month . Serum level ALAT and/or ASAT &gt; 50 UI/L time screen ( least 3 elevated transaminase value within last 12 month ) . Hepatic biopsy perform within last 18 month . A single normal transaminase value within last 12 month . Treatment ursodesoxycholic acid within last 12 month . Loss 15 % body weight time liver biopsy time screen . Alcohol consumption &gt; 20 g/day woman &gt; 30 g/day men Hepatitis cause : chronic viral hepatitis B C , elevate ferritin level associate C282Y homozygosity , primary biliary cirrhosis , primary sclerosing cholangitis , well document autoimmune hepatitis ( specific autoantibody , hypergammaglobulinemia , consistent histologic change ) , alpha1 antitrypsin deficiency , Wilson 's disease , HIV infection . NASH secondary cause : long term amiodarone administration , corticosteroid therapy , antiobesity surgery within last 2 year , tamoxifen . Child 's type B C cirrhosis . Presence hepatocellular carcinoma . Treatment rosiglitazone pioglitazone currently 3 precede year , treatment Vitamin E within 6 month prior screen . Women pregnant nursing . Unavailability hepatic biopsy slide centralize interpretation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>